Gilead Sciences
GILD
1,603 hedge funds and large institutions have $62.1B invested in Gilead Sciences in 2022 Q3 according to their latest regulatory filings, with 114 funds opening new positions, 741 increasing their positions, 536 reducing their positions, and 90 closing their positions.
56% more call options, than puts
Call options by funds: $1.19B | Put options by funds: $764M
38% more repeat investments, than reductions
Existing positions increased: 741 | Existing positions reduced: 536
34% more funds holding in top 10
Funds holding in top 10: 32 → 43 (+11)
27% more first-time investments, than exits
New positions opened: 114 | Existing positions closed: 90
1.08% more ownership
Funds ownership: 79.38% → 80.46% (+1.1%)
1% more capital invested
Capital invested by funds: $61.4B → $62.1B (+$672M)
0% less funds holding
Funds holding: 1,604 → 1,603 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$309M |
| 2 |
Amundi
Paris,
France
|
+$134M |
| 3 |
Bank of New York Mellon
New York
|
+$125M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$116M |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$113M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$229M |
| 2 |
Renaissance Technologies
New York
|
-$214M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$176M |
| 4 |
Morgan Stanley
New York
|
-$152M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
-$132M |
GILD Hedge Fund Activity: Q3 2022 in Review
1,603 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2022, worth a combined $62.1B — up 1.1% from $61.4B a quarter earlier.
Buyers outnumbered sellers: 114 funds opened new GILD positions and 90 closed out — a net gain of 24 holders — while 741 added to existing stakes and 536 trimmed.
The largest buyer was Capital World Investors, adding an estimated $309M. The largest seller was Arrowstreet Capital, cutting an estimated $229M.
- 1,603 institutional investors held Gilead Sciences (GILD) as of Q3 2022, down from 1,604 in Q2 2022.
- Funds reported $62.1B of Gilead Sciences stock for Q3 2022, up 1.1% quarter-over-quarter.
- 114 funds opened new Gilead Sciences positions in Q3 2022 and 90 closed out, a net change of +24 holders.
- The largest Gilead Sciences buyer in Q3 2022 was Capital World Investors, an estimated $309M added.
- The largest Gilead Sciences seller in Q3 2022 was Arrowstreet Capital, an estimated $229M sold.
Based on aggregated 13F filings for Q3 2022.